What is CSBR's P/E ratio?

Champions Oncology Inc (CSBR) currently trades at a P/E ratio of 245.19.

Champions Oncology Inc reports a Return on Equity (ROE) of -29.83%.

What is CSBR's dividend yield?

Champions Oncology Inc offers a dividend yield of 0.00%.

What is CSBR's Quality Score?

Our AI rates CSBR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CSBR?

Our AI Timing Score for CSBR is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CSBR belong to?

Champions Oncology Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Champions Oncology Inc (CSBR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-04-30)

CSBR AI Analysis Summary

Our AI summary for CSBR: Champions Oncology Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 245.19, ROE of -29.83%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CSBR

Champions Oncology Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 5.30

-0.15 (-2.75%) Day Change

Watchlist Portfolio Compare Chart

245.19

P/E

0.41

D/E

-29.8%

ROE

-4.4%

ROA

0.00%

Div Yield

-3.92

PEG

CHAMPIONS ONCOLOGY INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 5.30 Price -0.15 (-2.75%) Day Change	NEWS SCORE: 99

CSBR, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	1779
Magic Formula Rank by ROE	1779
Magic Formula Rank by ROIC	1793
Price	5.30
PBV / Sector	18.02 / 44,105.10
Earning Per Share	-0.08

PE / Sector	245.19 / 19.37
PEG or PE/Growth / Sector	-3.92 / 1.06
Average 1M Daily Value	0.05 M GREAT
Average 1W Daily Value	0.06 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1.98 / 97.23
NPM Average (%) / Sector	-4.53 / -1,697.84
NPM Change Average (%) / Sector	-78.12 / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-4.35 / 185,260.64
ROA Average (%) / Sector	-8.30 / 36,684.64
ROA Change Average (%) / Sector	-67.70 / 422,221.42
ROE (%) / Sector	-29.83 / 243,761.81
ROE Average (%) / Sector	90.52 / 48,758.38 GREAT
ROE Change Average (%) / Sector	-207.86 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:50
Symbol	CSBR
Name	CHAMPIONS ONCOLOGY INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	13.89 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	73.31 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: One University Plaza, Hackensack, NJ, United States, 07601

Phone: 201 808 8400

Website: https://www.championsoncology.com

Employees: 214

Sector: Healthcare >> Biotechnology

Description: Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.